Exploratory Clinical Trials for Small Business Grant Program
Page 2

That said, the NINDS seeks to provide support to small businesses in their quest to develop emerging technologies that will potentially be beneficial to the objective in focus.

The examples of the kinds of studies that will be supported under this program are those that aim to:

a) Evaluate and optimize the dose, formulation, safety, tolerability/pharmacokinetics of a certain intervention or diagnostic test in healthy volunteers or the target population

b) Prospective clinical validation of a diagnostic

c) Asses whether or not an intervention produces sufficient evidence of short-term activity in a human “proof of concept” trial

d) Determine the best of two or more potential interventions or dosing regimens that will be evaluated in a subsequent trial, based on tolerability, biological activity, or preliminary clinical efficacy.

The NIH and NINDS are set to administer a funding amount of $750,000 per grant awardee to support the execution of this program.

The institutions and organizations who will be considered eligible to submit an application under this program are those Small Business Concerns that meet the following criteria:

a) SBCs that are mainly organized for profit and is located and operating in the United States, and makes a substantial contribution to the United States economy through payment of taxes or use of American products, materials or labor;

b) SBCs that are in the legal form of an individual proprietorship, partnership, limited liability company, corporation, joint venture, association, trust or cooperative;

c) SBCs that does not have more than 500 employees

d) SBSs that are at least 51% owned and controlled by one or more individuals who are citizens of, or permanent resident aliens in, the United States.

Exploratory Clinical Trials for Small Business Grant Program
  Back to Page 1

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

The Collaborative Islet Transplantation Registry Program
The National Institutes of Health has formed a partnership with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in order to establish the The Collaborative Islet Transplantation Registry Program wherein both agencies seek to invite applications that intend to continue initiatives started through the Collaborative Islet Transplantation Registry (CITR).

---

Pilot Surveillance System for High Impact/Low Prevalence Congenital and Inherited Conditions Program
The Centers for Disease Control and Prevention has recently established the Pilot Surveillance System for High Impact/Low Prevalence Congenital and Inherited Conditions Program wherein it seeks to create and evaluate a surveillance system for congenital and inherited disease conditions.

---

Early-Stage Innovative Technology Development for Cancer Research Program
The National Institutes of Health has collaborated with the National Cancer Institute(NCI) in order to establish Early-Stage Innovative Technology Development for Cancer Research Program, wherein both agencies intend to solicit grant applications expressing intents to conduct funded exploratory research projects that concentrate on the inception and development unique, innovative technological advances that could potentially be utilized in the study of cancer.

---

National Institutes of Health funds the Improving Adherence to Treatment Regimens for HIV-Positive Adolescents and Young Adults
The National Institutes of Health has recently established a program entitled Improving Adherence to Treatment Regimens for HIV-Positive Adolescents and Young Adults wherein they intend to kick-off research studies that will create, implement, and evaluate both old and new interventions that are geared towards improving adherence to medical and behavioral regimens for HIV-positive adolescents which are 11 to 21 years old and adults who are 21 to 24 years old.

---